# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 EPAS ID: PAT6335341 Stylesheet Version v1.2

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 ASSIGNMENT

## **CONVEYING PARTY DATA**

Name	Execution Date
PAUL SUDHAKAR	06/29/2020
SCOTT BOYER	06/25/2020

## **RECEIVING PARTY DATA**

Name:	OWP PHARMACEUTICALS, INC.	
Street Address:	400 EAST DIEHL ROAD, SUITE 400	
City:	NAPERVILLE	
State/Country:	ILLINOIS	
Postal Code:	60563	

## **PROPERTY NUMBERS Total: 2**

Property Type	Number
Application Number:	62853800
Application Number:	15929929

## **CORRESPONDENCE DATA**

**Fax Number:** (612)436-9605

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6124369643

Email: DOCKETING@CARLSONCASPERS.COM

Correspondent Name: GARY J. SPEIER

Address Line 1: CARLSON, CASPERS, VANDENBURGH & LINDQUIST P.A.

Address Line 2: 225 S. SIXTH ST., SUITE 4200

Address Line 4: MINNEAPOLIS, MINNESOTA 55402

ATTORNEY DOCKET NUMBER: 1371.001PV, 1371.001US1

NAME OF SUBMITTER: GARY J. SPEIER

SIGNATURE: /Gary J. Speier/

DATE SIGNED: 10/05/2020

**Total Attachments: 2** 

source=Assignment (Executed) (1371.001PRV)#page1.tif source=Assignment (Executed) (1371.001PRV)#page2.tif

PATENT 506288593 REEL: 053974 FRAME: 0375

#### **ASSIGNMENT**

WHEREAS, Paul Sudhakar and Scott Boyer (hereinafter the "Assignors") have made one or more inventions and other subject matter (hereinafter collectively referred to as the "Invention") which are described in a patent application filed on May 29, 2019, which application was assigned U.S. Patent Application Serial No. 62/853,800, and which is titled LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF.

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency, and adequacy of which are hereby acknowledged by the Assignors, the Assignors do hereby irrevocably and unconditionally:

CONVEY, ASSIGN, AND TRANSFER to OWP Pharmaceuticals, Inc. (the "Assignee"), a corporation of the State of Illinois, having a place of business at 400 East Diehl Road, Suite 400, Naperville, IL 60563, the Assignor's entire right, title, and interest for the United States and all foreign countries and jurisdictions in and to:

the Invention which is disclosed in the above-identified application or applications;

such application or applications, and all divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other applications for a patent or patents which have been or shall be filed in the United States (including all provisional and non-provisional applications), and in all foreign countries and jurisdictions based in whole or in part on any of such Invention (including any application for a utility model or an innovation patent application);

all original and reissued patents which have been or shall be issued in the United States and all foreign countries and jurisdictions based in whole or in part on any of such Invention;

including the right to claim priority to the above-identified patent application or applications in relation to subject matter based in whole or in part on the above-identified patent application or applications and any of the foregoing including the right to file foreign applications under the provisions of any convention or treaty;

and including the right to all causes of action, remedies, and other enforcement rights related to the above-identified application or applications, including without limitation the right to sue for past, present, or future infringement, misappropriation, or violation of any and all rights related to the above-identified patent application or applications and any of the foregoing, including the right to obtain and collect damages for past, present, or future infringement;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such Invention to the Assignee;

AUTHORIZE AND REQUEST that any attorney associated with U.S. Patent and Trademark Office (USPTO) Customer No. <u>38846</u> may (directly or through his/her designee) delete, insert, or alter any information related to the above-identified patent application or applications or any of the foregoing, after execution of this Assignment;

PATENT REEL: 053974 FRAME: 0376

Attorney Docket No. 1371.001PRV

Assignment

Application No.: 62/853,800

Title: LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF

Page 2 of 2

WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or shall be made to others by the Assignors, and that the full right to convey the same as herein expressed is possessed by the Assignors;

COVENANT, that when requested and without compensation, but at the expense of the Assignee, in order to carry out in good faith the intent and purpose of this Assignment, the Assignors shall (1) execute all provisional, non-provisional, divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other patent applications for the Invention; (2) execute all rightful oaths, declarations, assignments, powers of attorney and other papers for the Invention; (3) communicate to the Assignee all facts known to the Assignors relating to the Invention and the history thereof; (4) cooperate with the Assignee in any interference, reexamination, reissue, opposition, dispute, or litigation involving any of the applications or patents for the Invention; and (5) take such further actions as the Assignee shall reasonably consider necessary or desirable for vesting title to such Invention in the Assignee, or for securing, maintaining and enforcing proper patent protection for the Invention;

COVENANT, that should any provision of this agreement be held unenforceable by an authority of competent jurisdiction, such a ruling shall not affect the validity and enforceability of the remaining provisions. To the extent that any such provision is found to be unenforceable, the Assignors, when requested and without compensation shall act in good faith to substitute for such provision a new provision with content and purpose as close as possible to the provision deemed unenforceable.

THIS AGREEMENT IS TO BE BINDING on the beirs, assigns, representatives, and successors of the Assignors, and is to extend to the benefit of the successors, assigns, and nominees of the Assignee.

AGREED as of the date of my signature below:

Signature:

Signature:

**RECORDED: 10/05/2020** 

**PATENT** REEL: 053974 FRAME: 0377